<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03857646</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-18-1000</org_study_id>
    <nct_id>NCT03857646</nct_id>
  </id_info>
  <brief_title>The Effect of Lipid Emulsions on Free Fatty Acids and Free Bilirubin in Premature Newborns</brief_title>
  <official_title>The Effect of Lipid Emulsions on Free Fatty Acids and Free Bilirubin in Premature Newborns</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this research study is to compare the levels of free fatty acids and free
      bilirubin between two intravenous lipid emulsion products in premature newborns.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2019</start_date>
  <completion_date type="Anticipated">April 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>free bilirubin serum levels</measure>
    <time_frame>first day of infusion at 3 g/kg/day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>free bilirubin serum levels</measure>
    <time_frame>second day of infusion at 3 g/kg/day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>unbound free fatty acid serum level</measure>
    <time_frame>first day of infusion at 3 g/kg/day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>unbound free fatty acid serum level</measure>
    <time_frame>second day of infusion at 3 g/kg/day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>free fatty acid (total) serum level</measure>
    <time_frame>second day of infusion at 3 g/kg/day of infusion at 3 g/kg/day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with peak serum triglyceride level &gt;350 mg/dl</measure>
    <time_frame>first and second days of infusion at 3 g/kg/day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean serum triglyceride level</measure>
    <time_frame>first and second days of infusion at 3 g/kg/day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Prematurity</condition>
  <arm_group>
    <arm_group_label>Intralipid</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SMOF lipid</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid, 20% Intravenous Emulsion</intervention_name>
    <description>Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.</description>
    <arm_group_label>Intralipid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SMOF lipid</intervention_name>
    <description>Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.</description>
    <arm_group_label>SMOF lipid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  premature newborns (&lt;32 weeks gestation, stratified &lt;28 weeks versus &gt;28 weeks) &lt;8
             days of age

          -  receiving lipid infusions &lt;1 g/kg/day at enrollment

          -  anticipated to be treated with 3 g/kg/day for a minimum of 48 hours.

        Exclusion Criteria:

          -  patients with direct hyperbilirubinemia &gt;1.5 mg/dl

          -  with suspected sepsis meeting Systemic inflammatory response syndrome (SIRS) criteria

          -  undergoing treatment with a continuous infusion of morphine

          -  with a continuous infusion of pressors (dopamine, dobutamine, epinephrine, etc.)

          -  positive blood cultures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>8 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cody Arnold, MD</last_name>
    <role>Study Director</role>
    <affiliation>UT Houston HSC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meredith Collins, MD</last_name>
    <phone>678-575-9580</phone>
    <email>meredith.d.collins@uth.tmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Texas Houston HSC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>February 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2019</study_first_posted>
  <last_update_submitted>February 28, 2019</last_update_submitted>
  <last_update_submitted_qc>February 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Cody Arnold</investigator_full_name>
    <investigator_title>Cody Arnold MD Associate Professor</investigator_title>
  </responsible_party>
  <keyword>parenteral nutrition</keyword>
  <keyword>lipid emulsion</keyword>
  <keyword>free bilirubin</keyword>
  <keyword>free fatty acids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

